A randomized, double-blind, 4-way crossover, placebo-controlled, phase II study to evaluate the efficacy and safety of TAC-202/bilastine in Japanese cedar pollinosis exposure to antigen in an environmental exposure chamber (EEC).

Trial Profile

A randomized, double-blind, 4-way crossover, placebo-controlled, phase II study to evaluate the efficacy and safety of TAC-202/bilastine in Japanese cedar pollinosis exposure to antigen in an environmental exposure chamber (EEC).

Completed
Phase of Trial: Phase II

Latest Information Update: 24 May 2016

At a glance

  • Drugs Bilastine (Primary) ; Fexofenadine
  • Indications Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 20 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top